Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

OtherAdvancedVery High Risk

DNP (2,4-Dinitrophenol)

Also known as: DNP, 2,4-Dinitrophenol, Dinitrophenol

DNP is an industrial chemical that acts as a mitochondrial uncoupler, dissipating the proton gradient used for ATP synthesis as heat. It was used as a diet drug in the 1930s before being banned due to a narrow therapeutic index and multiple fatalities. It remains in underground use for extreme fat loss.

Evidence55/100 — Moderate

Risk Level

Very High Risk

Difficulty

Advanced

CAS Number	51-28-5
Molecular Formula	C6H4N2O5
Class	Other
Category	Fat Loss Agents

Mechanism of Action

DNP inserts into the inner mitochondrial membrane and shuttles protons across, bypassing ATP synthase. This uncouples oxidative phosphorylation from ATP production, converting the energy from the proton gradient directly into heat. The body compensates by dramatically increasing metabolic rate and substrate oxidation, burning fat at an accelerated rate. There is no antidote for overdose.

Dosing Research

Underground protocols typically use 200-250 mg/day (crystal form), never exceeding 400 mg/day. Cycles are kept short (1-2 weeks). DNP accumulates due to a long half-life (~36 hours), so steady-state levels can be dangerously high. Extreme caution required; deaths have been reported at doses only slightly above common use levels.

Side Effects & Risks

Profuse sweating, dangerous hyperthermia, lethargy, nausea, rapid breathing, dehydration, cataracts (with chronic use), peripheral neuropathy, rash. Fatal hyperthermia is the primary cause of death. No antidote exists. Overdose leads to uncontrollable body temperature elevation and death. Multiple fatalities reported in bodybuilding and weight loss communities.

Research Studies

Related compounds

Semaglutide

Peptide

Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.

92/100Medium Risk

Tirzepatide

Peptide

Tirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.

90/100Medium Risk

Finasteride

Other

Finasteride is a selective type II 5-alpha reductase inhibitor approved for male pattern hair loss (1 mg, Propecia) and benign prostatic hyperplasia (5 mg, Proscar). It reduces scalp DHT levels by approximately 60-70% and is one of only two FDA-approved oral medications for androgenetic alopecia. It has decades of clinical data supporting its efficacy.